Despite its status as the standard therapy for multiple myeloma (MM), hematopoietic stem cell transplantation continues to be the source of study and consideration as new therapies for myeloma evolve. In this video, Adam D. Cohen, MD, offers his perspective on recent studies in the timing of autologous stem cell transplantation in MM and its potential role as a platform for immunotherapy, induction regimens in the pre-transplantation interim, and an assessment of the role of allogeneic transplantation.
Related Links
- Clinical Briefing: Restoration of Immunity in Lymphopenic Patients with Cancer via Immunotherapy with Vaccination and Adoptive T cell Transfer
- Case Study: A 51yearold man with a lytic lesion in the 7th rib, a compression fracture at T12, monoclonal IgA antibody in his blood, and a bone marrow biopsy showing 46% plasma cells, all consistent with the diagnosis of multiple myeloma
- Dr. Cohen’s Profile
Published
June 3, 2015
Created by
BROADCASTMED